Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Investigators to Present Preliminary Findings for Adaptimmune’s Gene Engineered T Cells in Myeloma

Published: Monday, November 19, 2012
Last Updated: Sunday, November 18, 2012
Bookmark and Share
Presentation of data at the annual ASH meeting on Monday 10 December.

Adaptimmune has announced the publication of dual abstracts in issue of the Journal Blood, which report preliminary results from an early phase study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells.

Lead investigators for the study will be presenting the data on December 10th at the annual meeting of the American Society of Hematology (ASH).

The trial was designed as a single arm open label extension study where patients are given standard of care (autologous stem cell transplant) in conjunction with modified T cells.

The critical step in this new approach is that the infused T cells have been genetically engineered to carry receptors that help the T cells recognize and attack a tumor, while sparing healthy tissue.

Study objectives are to evaluate the safety, bioactivity and anti-tumor effect of infusion of patients’ own T cells that have been genetically modified to express a high affinity T cell receptor (TCR) specific for a type of tumor antigen (protein) known as a cancer testis antigen (CT antigen). The target CT antigens in the study are NY-ESO-1 and LAGE-1.

The initial six patient phase is complete and patients have reached a minimum of six month follow-up for assessment of tumor response to the treatment.

Based on the encouraging preliminary results, which will be reported at the conference, the study has been extended to a target enrollment of 26 patients.

To date, infusion of modified T cells have been well tolerated. The data to be reported at the ASH meeting demonstrates prolonged persistence of modified T cells, homing of the cells to marrow (the site of tumor), and suggests anti-tumor activity.

Multiple myeloma is a hematologic cancer localized to the bone marrow. With standard therapy, long- term response rates are low, and the median survival for patients with this disease is three to five years.

The clinical trial focuses on this unmet medical need and includes patients who have received prior treatment for their myeloma or who have disease considered to be high risk, and who are eligible for an autologous stem cell transplant (auto-SCT).

Auto-SCT is the transplant of a patient’s own stem cells, which is a standard of care for treatment of multiple myeloma in the U.S. Infusion of the gene modified T cells occurs just following auto SCT.

Presentations at the ASH meeting will be made on Monday, December 10, in non-overlapping sessions.

Dr. Aaron Rapoport, the Chair of the clinical study, will present abstract 472 entitled “Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT”.

Dr. Michael Kalos, the lead correlative scientist on the study, will present abstract 755 entitled “Prolonged T Cell Persistence, Homing to Marrow and Selective Targeting of Antigen Positive Tumor in Multiple Myeloma Patients Following Adoptive Transfer of T Cells Genetically Engineered to Express an Affinity-Enhanced T Cell Receptor against the Cancer Testis Antigens.”

In addition, Dr. Carl June, study sponsor and recipient of the 2012 prestigious Ernest Beutler Award for major translational advances, will present data from the study at the Beutler Lecture, also on Monday.

“I am very pleased to speak about this promising study at ASH this year,” says Dr. June. “Adaptimmune’s technology is an important component of the next generation of cancer therapies predicated on harnessing the power of the T cell.”

“From a clinical perspective, I am encouraged by these preliminary findings which will enable us to continue to evaluate T cell therapy for myeloma, and I look forward to the opportunity to present the data for review in a national forum,” says Dr. Rapoport.

Despite the preliminary nature of the study, we have learned a lot already from our careful and integrated analyses of blood, marrow and serum in these patients,” says Dr. Kalos. “This allows us to correlate the engraftment, cytokine production and also changes in target tumor antigen over time, and to demonstrate anti-tumor activity of the infused cells in vivo”.

“We are tremendously pleased with the emerging clinical data in our myeloma programme,” says Dominic Smethurst, Medical Director at Adaptimmune. “We are working with a world class team of investigators, who are very engaged with ensuring the clinical advancement of this technology.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Tuesday, July 21, 2015
Adaptimmune Secures $104 Million in Series A Financing
Company will use funding to advance programmes in multiple cancer indications.
Friday, September 26, 2014
Adaptimmune Announces Full-time Appointment of James Noble as CEO
Appointment will become effective from 31st March.
Thursday, March 27, 2014
Adaptimmune Awarded £2.1m from the Biomedical Catalyst Fund
The prestigious award supports Adaptimmune’s clinical pipeline expansion.
Tuesday, March 25, 2014
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells
Study continues to report encouraging response rates, safety and proof of mechanism.
Thursday, December 12, 2013
Adaptimmune Announces Opening of Phase I/IIa Clinical Trial
Adaptimmune announced that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer.
Thursday, July 25, 2013
NeoStem’s Subsidiary, PCT Enters into Services Agreement with Adaptimmune
PCT to provide cell product development and manufacturing for Adaptimmune’s clinical trials.
Thursday, January 24, 2013
Adaptimmune Announces Preliminary Results from an Early Phase Trial of Gene Engineered T Cells
Study reports encouraging response rates, and data support safety and preliminary proof of mechanism.
Tuesday, December 11, 2012
Adaptimmune Announces New Board Appointments
Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director both with immediate effect.
Monday, September 26, 2011
Adaptimmune Announces New Board Appointments as Clinical Programmes Get Underway
Company prepares to open trials in further cancer indications in 2012.
Thursday, September 22, 2011
Adaptimmune Announces Opening of Phase I/II Clinical Trial for Metastatic Melanoma
The Phase I/II, two cohort, open label clinical trial in metastatic melanoma opens at Washington University, St. Louis, Missouri.
Monday, June 20, 2011
Scientific News
Removing 62 Barriers to Pig–to–Human Organ Transplant in One Fell Swoop
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Gene Editing Could Enable Pig-To-Human Organ Transplant
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
UC San Diego Team Up with Illumina to Speed-Read Your Microbiome
Data analysis app accelerates studies aimed at using microbes to predict, diagnose and treat human diseases.
Paving the Way for Diamonds to Trace Early Cancers
Researchers from the University of Sydney reveal how nanoscale 'diamonds' can light up early-stage cancers in MRI scans.
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos